Related Experiment Video
Updated: Aug 26, 2026
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Analysis of Fas (Apo-1/CD95) expression in non-small cell lung cancer
Vincenzo Esposito1, Alfonso Baldi, Giuseppina Liuzzi
1Third Division of Infective Diseases, D. Cotugno Hospital, Department of Cardiological, Respiratory and Thoracic Medical Sciences, Second University of Naples, Naples, Italy.
Abstract:
Defects in the apoptotic pathway represent a critical element in the progression of neoplastic disease and may also concur to determine treatment efficacy at the cellular level. Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling. In this study we analyzed, by immunohistochemistry, the expression of Fas protein in a group of 68 NSCLC (non-small cell lung cancer) specimens. Statistical analyses did not show any significant relationship between Fas immunohistochemical expression and clinical parameters of lung cancer patients, except for nodal status. Our data do not support the use of Fas as a molecular prognostic role in NSCLC. On the other hand, considering the role of the Fas-pathway in chemotherapy-induced apoptosis, further studies are required to analyze the potential value of Fas expression in predicting the response of NSCLC patients to chemotherapy.
Insights
Defects in apoptosis, crucial for cancer, were studied. Fas protein expression in non-small cell lung cancer (NSCLC) showed no clear prognostic value but may predict chemotherapy response.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Apoptotic pathway defects are key in cancer progression and treatment response.
- Fas (Apo-1/CD95) is a cell-surface receptor critical for initiating apoptosis (programmed cell death).
Purpose of the Study:
- To investigate the expression of Fas protein in non-small cell lung cancer (NSCLC).
- To determine if Fas expression correlates with clinical parameters or serves as a prognostic marker in NSCLC.
- To explore the potential of Fas expression in predicting chemotherapy response in NSCLC patients.
Main Methods:
- Immunohistochemistry was used to analyze Fas protein expression.
- The study included 68 specimens of non-small cell lung cancer (NSCLC).
- Statistical analyses were performed to correlate Fas expression with clinical parameters.
Main Results:
- No significant relationship was found between Fas immunohistochemical expression and most clinical parameters in NSCLC patients.
- A significant relationship was observed only between Fas expression and nodal status.
- Fas expression did not emerge as a reliable molecular prognostic marker for NSCLC in this cohort.
Conclusions:
- Fas protein expression does not appear to have a significant prognostic role in non-small cell lung cancer (NSCLC).
- The Fas pathway's role in chemotherapy-induced apoptosis suggests further research is needed.
- Investigating Fas expression may be valuable for predicting NSCLC patient response to chemotherapy.
